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Summary.-Monoclonal antibodies against 2 human lung carcinoma cell lines (E14
and BEN) were prepared by production and cloning of somatic cell hybrids between
the murine myeloma NS1, and spleens from E14- and BEN-immune BALB/c mice.
Approximately 2000 hybrid culture supernatants were screened for antibody
simultaneously against the immunizing cell line and lung fibroblasts (573 Lu) using a
radiolabelled Protein A binding assay. Although the vast majority secreted
antibodies which recognized species-specific antigens, a few supernatants showed
marked differential reactivity against E14 or BEN. These were cloned and
subsequently tested against a panel of up to 25 human cell lines originating from
different neoplastic and non-neoplastic tissues. Two anti-E14 clones (3E19.8 and
4EAB3.7) displayed preferential activity against lung cancer cell lines, but a low level
of reactivity was also detectable with cell lines of different tissue provenance. The
antibodies of 3 anti-BEN clones (7B3.5, 7B5.4, 7B17.7) likewise recognized antigens
present to a higher density on lung cancer cell lines but were also reactive (to a
variable extent for the different clones) with a diversity of other tumour cell lines.
The antibodies of 2 further clones were exceptional in so far as one (7BC9.1) reacted
only with BEN and WIDR (colorectal cancer) cells, while another (7B24.4) reacted,
with apparent exclusivity, against BEN cells. With the exception of the latter, the
distinction in antigen expression between many of the cell lines was quantitative
rather than qualitative and the emergent picture is one of random expression of
individual determinants on several disparate types of cancer cells, rather than
restriction to cells of a given morphological type or histogenic derivation.
SINCE the description by Kohler &
Milstein (1975) of somatic cell-hybridiza-
tion as a means of generating monoclonal
antibodies to cell-surface antigens, a
considerable body of data has already
accumulated on the expression of such
antigens on human tumours. Earlier
claims oftissue-site specificity and even of
unique tumour specificity for some neo-
plasms (e.g. malignant melanoma, colorec-
tal carcinoma, neuroblastoma (Koprowski
et al., 1978; Yeh et al., 1979; Kennett &
Gilbert, 1979; Carrel et al., 1980) have
more recently given place to reports of
greater complexity in antigen distribution,
including, for example, apparently ran-
dom expression not associated with any
particular tumour type (Embleton et al.,
1981), and cross-reactivity between differ-
ent tumours (malignant melanoma and
brain) of common embryological deriva-
tion (Liao et al., 1981).
The evocation of monoclonal antibodies
to human carcinoma of lung has received
limited attention to date. Sikora & Wright
(1981) generated antibodies from inter-
species hybrids of hilar and bronchial
lymph nodes, with rat or mouse myeloma
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cells, which were preferentially reactive
with lung tumour cell membranes, in
comparison with those of normal lung
tissue. Other investigators, using estab-
lished cell lines as immunogens, have
developed intraspecies hybrids producing
antibodies recognizing antigens ofvariable
distribution on lung and other cancer cells
(Kasai et al., 1981; Cuttitta et al., 1981).
In this study the distribution of
antigens expressed on cultured lung cancer
cells and on tumours of different proven-
ance and histology was investigated by the
production of monoclonal antibodies to
two well-characterized cell lines (E14 and
BEN) originating from squamous cell
carcinoma of the bronchus (Fischer &
Vetterlein, 1977; Ellison et al., 1975; Ham
etal., 1980;Lumsdenetal., 1980).
METHODS AND MATERIALS
Ce118.-The parental myeloma line used in
these experiments was P3-NSI-I-Ag4-1 (NS1)
(Flow Laboratories, Irvine, Scotland). Cells
were grown in suspension in DMEM supple-
mented with 10% foetal bovine serum (FBS)
and 1 mM pyruvate (Flow Labs) and sub-
cultured at 2 x weekly intervals. Frozen
stocks were maintained at -70TC in 90%
newborn calf serum (NBCS) and 10%
dimethyl sulphoxide (Sigma Chemical Co.,
U.S.A.). Cells used in fusion experiments were
harvested during the logarithmic phase of
growth, washed x 2 with serum-free DMEM
and routinely checked for aminopterin sensi-
tivity before fusion.
The IgG1 secreting mouse myeloma line P3-
X63-Ag8 (X63) was maintained as for NS1, as
a source of control murine antibody-con-
taining supernates in the binding assays.
Various human cell lines of different
provenance and morphology were used in this
study (Table). These were routinely main-
tained in DMEM plus 10% FBS orNBCS. For
passage, cells were disaggregated using 0-1%
trypsin (Sigma), 0-02M ethylene diamine
tetracetic acid (EDTA) (BDH Chemical Ltd,
U.K.) in Hanks' balanced salt solution
(HBSS). For immunization and binding
assays, cells were harvested mechanically
where possible, but if trypsin/EDTA was
necessary, cells were allowed to recover 24 h
in culture medium in siliconized glass bottles
(Repelcote, Hopkins and Williams, U.K.).
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TABLE.-Human cell lines usedas targets in
binding assays
Tissue origin
Lung squamous carcinomaa
Lung adenocarcinoma
Lung oat cell carcinoma
Lung carcinoma (unspecified)
Lung carcinoma (fibroblastic)
Normal lung (fibroblastic)
Colorectal. carcinoma
Liver
Osteosarcoma (fibroblastic)
Malignant melanoma
Burkitt lymphoma
Cervical carcinoma
Ovarian carcinoma
Prostate carcinoma
Bladder carcinoma
Designation in text
E14, BEN
MORb
FRE*, MAR*
A549
573, 618T, 756T
573Lu, 618Lu, 756Lu
WIDR, HT29, HCT8
Chang
791T, 788T
RPMl 5966
Raji
HeLa
PA-1
EB33T
T24
a All cultures given asepithelial monolayersexcept
where otherwise stated.
b Derived from a lung tumour xenograft (Short-
house et al., 1980).
Freedom from mycoplasma contamination
was regularly checked bymicroscopic examin-
ation with the DNA-specific fluorescent
Hoechst 33258 stain (Chen, 1977; Boyle et al.,
1981).
Immunization.-BALB/c mice were im-
munized with E14 and BEN cells. Two
fusions (3E and 4EAB) were carried out with
spleens from mice which hadreceived 107 E14
cells in 0 1 complete Freund's adjuvant (CFA)
i.p. on Days 1 and 15, followed by a booster
i.v. injection of 2 x 106 E14 cells in 0-1 ml
PBS 4 days before fusion. [For the 4EAB
fusion, cells of the final i.v. inoculum were
precoated with mouse antiserum against the
normal lung fibroblast line, 573Lu, in an
attempt to mask unwanted specificities
(Kennett & Gilbert, 1979)]. It was considered
unnecessary to use coated cells in the
preliminary immunizations since normally
only those antigen-reactive cells which receive
a specific stimulus immediately prior to fusion
produce hybrids (Kennet et al., 1980). Two
further fusions (5E and 6E) were conducted
with spleens from (i) mice which received an
additional i.p. injection of 107 E14 cells in
CFA on Day 32, prior to an i.v. boost, with
2 x 106 untreated cells on Day 51; and (ii)
mice which received only a single i.p. injection
on Day 1 and an i.v. boost, also with
untreated cells on Day 18. In both instances,
fusion was carried out 3 days after the final
i.v. immunization.
A single fusion (7B) was performed with
spleen cells from mice immunized with BEN
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cells, the immunization schedule comprising a
single i.p. injection of107 cells in 0 1 ml (CFA)
on Day 1, and a booster i.v. injection of
5 x 106 uncoated cells on Day 16. Fusion was
conducted 3 days later.
Celltfusion.-Spleens were removed aseptic-
ally and cell suspensions prepared by teasing
fragments in DMEM. These cells (108) were
then fused with NS1 cells (107) using 50%
(v/v) polyethylene glycol (PEG), after the
basic method of Galfre et al. (1977), under
conditions capable of generating 3000-5000
hybrids per fusion. To avoid overgrowth of
antibody-producing hybrids by non-
producing hybrid cells, fused cells were plated
at a low density into multiple 96-well tissue
culture plates, with extraneous unfused
"feeder cells" (spleen cells from mice immune
to an irrelevant antigen) to foster hybrid
colony development. Supernatants were
simultaneously screened for reactivity against
the immunizing cell lines, E14 and BEN, and
the normal lung fibroblast line, 573Lu, using a
1251-labelled protein A binding test. Selected
positive hybridomas were cloned by limiting
dilution.
1251 Protein A Binding Assay.-Protein A
(Pharmacia, Sweden) was iodinated by the
chloramine T method (Hunter, 1978). Har-
vested cells (2 x 105 cells/25 pul PBS contain-
ing 1% bovine serum albumin (BSA) were
admixed with test supernate (50 ,ul) in round-
bottomed microtitre plates (Flow Labor-
atories). After incubation at 4TC for 45 min,
the cells were washed x 3 by centrifugation
and 1251-labelled protein A (diluted in wash
buffer to give an input of approx. 1-2 x 105
ct/min) added. Following further incubation
at 4°C for 45 min the cells were again washed
x 3 and the pellet andwashings transferred to
LP3 tubes (Luckham Ltd, U.K.) for y-count-
ing. Each supernate was assayed in triplicate
and the results expressed as mean ct/min
minus background values which varied for
each target (as determined by control
supernates derived from the IgG, secreting
X63 mouse myeloma line) or as a ratio of
ct/min bound divided by background values.
More rapid screening for antibodies reactive
with adherent cell lines was achieved using a
monolayer assay. For this purpose, trypsin-
ized targets (5 x 104-5 x 105 in 200 ,ul med-
ium) were added to wells of flat-bottomed
microtitre plates (Gibco Europe Ltd), each of
which contained a single sterile 6 mm round
glass coverslip (Chance-Propper Ltd, U.K.).
Confluent monolayers were obtained between
2 and 5 days depending on the input number
and these were fixed with glutaraldehyde
(0 25% in PBS) (BDH Chemicals Ltd, U.K.)
for 10 min at room temperature to improve
adherence, washed and maintained at 4°C
under PBS containing BSA (for <3 days)
before deployment in the binding assay. This
was carried out essentially as for the
suspension assay except that centrifugation
was obviated and coverslips were transferred
direct to LP3 tubes for counting. Comparison
of data obtained with the same targets in
suspension and monolayer assays indicated
that they could be used interchangeably.
Suspensions were used for specificity analysis
and the monolayer modification for screening
where large numbers of supernates were
involved.
RESULTS
Monoclonal antibodies against El4
Supernates of 46/485 (9.5%) wells
screened from 10 x 96 well microtitre
plates of one fusion (3E) contained anti-
bodies reactive with E14 cells, the major-
ity ofwhich were also reactive with 573Lu
cells.
Cells generating supernatants with pro-
portionately greater anti-E14 reactivity as
well as a number equally reactive with
573Lu cells were cloned. Some hybrids
which showed only low reactivity in the
primary assays, failed to generate a stable
antibody-producing hybrid (presumably
on account of instability of the original
antibody-producing cells).
Fig. 1 shows the reactivity of different
3E hybridoma lines against various targets
in suspension assays. 3E10.2 and 3E22.1
antibodies reacted with 2/3 lung car-
cinoma cell lines, a colorectal carcinoma
cell line (WIDR) as well as the normal
573Lu line, while the 3E11.5 antibody
reacted with all cell lines against which it
was tested. The 3E14.5 antibody also
reacted with all cell lines although binding
was greater with the 5 epithelial carcinoma
lines (especially E14) than with the lung
fibroblast lines. The 3E19.8 antibody
reacted most strongly with the carcinoma
cell lines of lung origin (again especially
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with E14 itself), but binding was also
detectable against other epithelial cancer
cells, lymphoblastoid Raji cells and fibro-
blast lines. This pattern of reactivity
suggested the recognition of the antigen
predominantly expressed on most lung
cancer cell lines but also present on various
other cell lines including some of non-
pulmonary origin and possibly also ofnon-
neoplastic phenotype.
In a second fusion (4EAB), supernates
of 37/235 wells (16%) contained anti-E14
antibodies. As in fusion 3E, most of these
were also reactive against 573Lu cells.
However, one supernatant (4EAB3)
showed a relatively greater binding to
E14. The corresponding hybridoma was
subsequently cloned and the antibody
tested for reactivity against the larger
panel of targets (Fig. 2).
Antibodies secreted by the 4EAB8.2
and 4EAB10.4 clones bound to varying
degrees to all the cell lines tested. By
contrast, the product of clone 4EAB3.7
showed significant binding with only 4 cell
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lines, of which 3 were lung carcinomas
(E14, BEN, MOR) and the fourth a
colorectal carcinoma line (HT29).
Two further fusions (5E and 6E) based
upon different immunization protocols
from which a total of 695 hybrids were
screened failed to generate any antibodies
reactive with E14 cells which were not also
reactive to varying degrees, with 573Lu.
Monoclonal antibodies against BEN
Supernates of 60/286 (42%) and 53/240 (430) wells screened of one fusion (7B)
contained antibodies reactive with BEN
and E14 cells respectively, the majority of
which were also reactive with 573Lu.
However, several supernatants showed a
reactivity which suggested the recognition
ofantigens present at different densities on
the 2-types of cell lines. The hybridomas
producing these supernatants were cloned
and the specificity of the supernatants
assayed against all 3 cell lines. Of 28 wells
cloned, 24 produced stable hybridoma
7B5.4 7B17.7
Target cell line
FIG. 3. Reactivity of 7B hybrid supernatants with various human cell lines. * Significant
binding P <0 05.
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lines, of which 16 produced anti-E14
and/or anti-BEN antibodies.
Another group of 96 hybridomas from
this fusion were cloned and the super-
natants (termed 7BC) screened simul-
taneously against both lung carcinoma cell
lines and against normal lung cells.
While the majority of these were
polyspecific (i.e. reactive against 573Lu in
addition to E14/BEN), or (in one instance)
reactive with serum components, one
supernate (designated 7BC9) was identi-
fied as of potential importance in that it
appeared to discriminate between BEN
and E14 cells.
Supernatants from several cloned lines
resulting from this fusion (7B and 7BC
hybrid lines) were tested in suspension for
reactivity against the cell line panel. Fig. 3
shows the binding data for 3 monoclonal
antibodies which showed a more varied
pattern of reactivity. The 7B3.5 antibody
reacted with all 5 lung carcinoma lines
tested, but with only one of 4 fibroblastic
lung lines. It also bound to 1/2 colorectal
carcinoma lines (HT29), 2/2 osteosarcoma
lines (791T and 788T) and single lines
derived from malignant n,elanoma (RPMI
15
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0
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Fiea. 4. Reactivity of 7B hybrid supernatants
with various human cell lines. * Significant
binding P < 0 05.
5966) and bladder (T24) and cervical
(HeLa) carcinomas. Other carcinomas (of
ovarian and prostatic origin) and the Raji
cell line were negative. The 7B5.4 anti-
body also bound to all the lung cancer lines
as well as 5/7 other epithelial cancers, 2
osteosarcoma cell lines, the malignant
melanoma line RPMI 5966 and Raji, but
was negative with all 4 fibroblast lines, the
ovarian carcinoma PAI and prostatic
carcinoma EB33J. The reactivity of the
7B17.7 antibody was more variable. The
antigen was present on E14 (but not A549
cells) as well as at low density on the
fibroblastic lung lines, an osteosarcoma
cell line, 2 other epithelial cancers and the
melanoma line.
Two monoclonal antibodies were pro-
duced which recognized a target antigen of
very restricted distribution. The 7BC9.1
antibody bound only to the immunizing
lung carcinoma BEN and at a much lower
degree to the colorectal carcinoma cell line,
WIDR (Noguchi et al., 1979). Also, the
7B24.4 antibody recognized a determinant
expressed at high density only on the
immunizing BEN cell line but which was
undetectable on 12 other human cell lines
tested (Fig. 4). The specificity of these
latter antibodies was thus greater than
any other generated in the study.
None of the antibodies showing any
selectivity for the human cell lines was
reactive with sheep or human red blood
cells (of whatever major group).
DISCUSSION
From all fusions with spleens from mice
immunized with E14 cells, the frequency
of monoclonal antibodies reactive with
cell-surface antigens of restricted distri-
bution was low. Widely cross-reacting,
species-specific antigens were the immuno-
dominant determinants giving rise to these
antibodies, the elicitation of which was
largely independent of the immunization
protocol. Even coating E14 cells with
murine antiserum against the lung fibro-
blast 573Lu line for the final i.v. injection,
a procedure designed to mask the response
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to unwanted determinants (Kennett &
Gilbert, 1979) failed to yield antibodies
with more restricted specificity.
Only 2 clones (3E19.8 and 4EAB3.7) of
150 producing anti-E14 antibody
appeared to be recognizing antigens pre-
dominantly associated with lung
carcinoma cells. For the 3E19.8 antibody
the distinction was essentially quantita-
tive in so far as, although reactivity with
lung cancer cell lines (especially El4) was
greatest, a low but significant level of
binding was also detectable against lung
tumour-derived cells of fibroblast mor-
phology, transferred B cells (Raji), and 2/3
colorectal carcinomas. Greater selectivity
was displayed by antibody ofthe 4EAB3.7
clone. The antigen detected by this
antibody was found only on lung car-
cinoma cell lines (E14, BEN, MOR), on 1/3
colorectal carcinoma lines, but was absent
from 15 other human cell types. This
virtually excludes the possibility that the
antigen is an FBS component incorporated
into the membrane of cells grown in
medium containing supplementary FBS
(Irie et al., 1974; Embleton & Jype, 1978).
However, it is possible that the antibody
reacts with antigens acquired by some cells
as a consequence ofin vitro passage, rather
than with antigens associated with the
transformed state. For this reason, pros-
pective testing of antibodies by immuno-
histology should be used to amplify
binding assays against select cell lines
(Finan et al., 1982). Even so it appears that
this antibody reacts with a determinant
expressed ony by certain human carcin-
oma cells ofdifferent origin.
Similar overall, but individually vari-
able patterns of reactivity were observed
for clones producing anti-BEN antibodies
(7B3.5, 7B5.4, 7B17.7). The target anti-
gens recognized by these antibodies again
appear to be present at a higher density on
most lung cancer cell lines and a variety of
other epithelial, and mesenchymal can-
cers, but not on fibroblasts. Provisionally,
therefore, these antibodies appear to be
detecting antigens predominantly associ-
ated with the neoplastic state, but further
specificity testing is necessary to confirm
this. Since the antibodies react with both
epithelial and mesenchymal tumour cells it
would appear that they are not recog-
nizing differentiation antigens. Also the
pattern ofreactivity is not what one would
expect against polymorphic histocom-
patibility determinants. Likewise, Fors-
sman antigen and major blood group
antigens could be discounted since no
reaction with these antibodies was
obtained against human or sheep red blood
cells.
One monoclonal antibody (7B24.4)
appeared to react only with the immuniz-
ing cell line, BEN, while another (7BC9.1)
reacted with BEN and one other (color-
ectal cancer) cell line (WIDR). Again, the
possibility that these antibodies are de-
tecting antigens expressed adventitiously
and in the case of 7B24.4, exclusively by
BEN cells as a result of in vitro passage
cannot be excluded. It is also possible that
they are recognizing rare histocompati-
bility determinants virtually confined to
this cell line. Since the antibodies were
unreactive toward other lung carcinoma
cell lines, the target antigens are clearly
not of widespread occurrence but whether
this antigen is a truly unique product of
the BEN cell line would require much
more extensive testing.
Our experience in this study leads us to
tentatively conclude that the antigens on
human cell lines recognized by monoclonal
antibodies raised against them are some-
what randomly distributed and not un-
equivocally associated with lines derived
from tumours of any particular histo-
logical type or tissue origin. In particular,
evidence that human tumours express
antigens common to neoplasms arising in a
given tissue as formulated originally for
several human cancers, has been conspic-
uously lacking. However, our data are
consistent with more recent reports that
antigens including some ofdefined molec-
ular weight (AMazauric et al., 1982)-
expressed on lung cancer cells may also be
shared to a variable degree by non-
pulmonary cancers (Kasai et al., 1981;
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Cuttitta et al., 1981). To this extent,
reagents of the type generated in this
study offer potentially a productive means
of delineating the complex antigenic
profiles of human lung cancer. Implicit in
our findings and those of other investiga-
tors, however, is the notion that the
phenotyping of human cancers for diag-
nostic and therapeutic exploitation will
probably entail the generation ofpanels of
mouse monoclonals recognizing many
different determinants.
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